NOXSignificant results from new brain cancer drugs asChroma...

NOX

Significant results from new brain cancer drugs as
Chroma platform matures
Highlights
• Novel brain cancer drug candidates significantly reduce tumour growth
• Important ability to cross blood-brain barrier
• Promising early Chroma™ drug candidate for leukaemia
Sydney, 3 September 2024: Innovative biotech company Noxopharm Limited (ASX:NOX) is
pleased to announce substantial progress on its Chroma™ technology platform, with
encouraging brain cancer results plus early work on leukaemia.
Glioblastoma is the most frequent and lethal type of brain cancer, accounting for two-thirds
of all Australian brain cancers. It remains an incurable disease with a median survival time of
just 15 months after diagnosis. Today there are only a few treatment options available, and
after initial treatment recurrence of the disease is almost inevitable.
The global glioblastoma market was worth around US$2.9 billion in 2022 and is expected to
grow at an annual rate of 8.8%.